Share

News kindly supplied by Kresimir Babic

10 August 2011

(….) Lu AA24493 is an interesting  tissue protective  cytokine with potential for addressing medical needs in a number of severe CNS diseases. In November  2009,  Lundbeck initiated a phase IIa  clinical study with this innovative compound in patients suffering from Friedreich’s ataxia in order to explore efficacy parameters of the drug via biomarkers as well as to evaluate the safety and tolerability of Lu AA24493.
In the study,  Lu AA24493 did not meet the key efficacy endpoints and the results  do not support  further development  of the drug in Friedreich’s ataxia. (...)

Source:  Lundbeck press release (pages 5 and 6 of 22)